ORIGINAL ARTICLE
The role of the CLL-1 protein in disease monitoring in patients diagnosed with acute myeloid leukaemia and myelodysplastic syndrome
1
Department of Pathology, Pomeranian Medical University, Szczecin, Poland
2
Department of Haematology and Transplantology, Pomeranian Medical University, Szczecin, Poland
3
Department of Tumour Pathology, Greater Poland Cancer Centre, Poznań, Poland
Submission date: 2024-01-28
Acceptance date: 2024-09-06
Publication date: 2024-10-16
Corresponding author
Sylwia Romana Jankowska-Szabłowska
Sylwia Romana Jankowska-Szabłowska, PhD Pomeranian Medical University Szczecin, Poland
Sylwia Romana Jankowska-Szabłowska, PhD Pomeranian Medical University Szczecin, Poland
Pol J Pathol 2024;75(3):182-191
KEYWORDS
TOPICS
ABSTRACT
The normal subpopulation of CD34+CD38 – haematopoietic stem cells does not express CLL-1; therefore, the assessment of the expression of this protein can be used for the diagnosis of minimal residual disease. The aim of this study was to evaluate, using multi-colour flow cytometry, the level of CLL-1 protein expression on CD34+CD38- myeloid niche cells in acute myeloid leukaemia (AML) and myelodysplastic syndromepatients at the time of diagnosis and during disease monitoring on the example of 3 practical cases. The following conclusion was drawn: CD34+CD38-CLL-1+ cells in AML patients may serve as a biomarker to predict disease aggressiveness.
REFERENCES (49)
1.
Freeman SD, Virgo P, Couzens S, et al. Prognostic relevance of treatment response measured by Flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 2013; 31: 4123-4132.
2.
Buccisano F, Hourigan CS, Walter RB. The prognostic significance of measurable (“minimal”) residual disease in acute myeloid leukemia. Curr Hematol Malig Rep 2017; 12: 547-555.
3.
Bachas C, Schuurhuis GJ, Assaraf YG, et al. The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia 2012; 26: 1313-1320.
4.
Kersten B, Valkering M, Wouters R, et al. CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia. Brit J Haematol 2016; 173: 219-235.
5.
Terwijn M, van Putten WLJ, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013; 31: 3889-3897.
6.
Zeijlemaker W, Kelder A, Cloos J, et al. Immunophenotypic detection of measurable residual (stem cell) disease using LAIP approach in acute myeloid leukemia. Curr Protoc Cytometr 2019; 91: e66.
7.
Van Rhenen A, Moshaver B, Kelder A, et al. Aberrant marker expression patterns on the CD34 þ CD38 stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 2007; 21: 1700-1707.
8.
Bruserud Q, Aasebø E, Hernandez-Valladares M, et al. Therapeutic targeting of leukemic stem cells in acute myeloid leukemia – the biological background for possible strategies. Exp Opin Drug Disc 2017; 12: 1053-1065.
9.
Dix C, Lo TH, Clark G, et al. Measurable residual disease in acute myeloid leukemia using flow cytometry: a review of where we are and where we are going. J Clin Med 2020; 9: 1714.
10.
Appelbaum FR. Hematopoietic cell transplantation for adults with acute myeloid leukemia with minimal residual disease. Best Pract Res Clin Haematol 2015; 28: 133-140.
11.
Roug AS, Larsen HØ, Nederby L, et al. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone – a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia. Br J Haematol 2014; 164: 212-222.
12.
Zeijlemaker W, Gratama JW, Schuurhuis GJ. Tumor heterogeneity makes AML a “moving target” for detection of residual disease. Cytometry B Clin Cytom 2014; 86: 3-14.
13.
Zeijlemaker W, Grob T, Meijer R, et al. CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia 2019; 33: 1102-1112.
16.
Yanagisawa B, Ghiaur G, Smith BD, et al. Translating leukemia stem cells into the clinic: harmonizing the heterogeneity. Exp Hematol 2016; 44: 1130-1137.
17.
Joshi K, Zhang L, Breslin PSJ, et al. Leukemia stem cells in the pathogenesis, progression, and treatment of acute myeloid leukemia. Adv Exp Med Biol 2019; 1143: 95-128.
18.
Darwish NHE, Sudha T, Godugu K, et al. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1. Oncotarget 2016; 7: 57811-57820.
19.
Terwijn M, Zeijlemaker W, Kelder A, et al. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One 2014; 9: 1-14.
20.
Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med 2018; 378: 1189-1199.
21.
Getta BM, Devlin SM, Levine RS, et al. Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation. Biol Blood Marrow Transplant 2017; 23: 1064-1071.
22.
Venditti A, Piciocchi A, Candoni A, et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood 2019; 134: 935-945.
23.
Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018; 131: 1275-1291.
24.
Leong SR, Sukumaran S, Hristopoulos S, et al. An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia. Blood 2017; 129: 609-618.
25.
Bakker ABH, van den Oudenrijn S, Bakker AQ, et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with Acute Myeloid Leukemia. Cancer Res 2004; 64: 8443-8450.
26.
Van Rhenen A, van Dongen GAMS, Kelder A, et al. The novel AML stem cell–associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007; 110: 2659-2666.
27.
Pelosi E, Castelli G, Testa U. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells. Blood Cells Mol Dis 2015; 55: 336-346.
28.
Gasiorowski RE, Clark GJ, Bradstock K, et al. Antibody therapy for acute myeloid leukaemia. Br J Haematol 2014; 164: 481-495.
29.
Gerber JM, Smith BD, Ngwang B, et al. A clinically relevant population of leukemic CD34+CD38- cells in acute myeloid leukemia. Blood 2012; 119: 3571-3577.
30.
Lacombe F, Durrieu F, Briais A, et al. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 1997; 11: 1878-1886.
31.
Larsen HØ, Roug AS, Just T. Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up. Cytometry B Clin Cytom 2012; 82: 3-8.
32.
Haubner S, Perna F, Köhnke T, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia 2019; 33: 64-74.
33.
Coustan-Smith E, Song G, Shurtleff S, et al. Universal monitoring of minimal residual disease in acute myeloid leukemia. JCI Insight 2018; 3: e98561.
34.
Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJM, et al. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia 2016; 30: 439-446.
35.
Toft-Petersen M, Nederby L, Kjeldsen E, et al. Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome. Br J Haematol 2016; 175: 393-401.
36.
Woll PS, Kja U, Chowdhury O, et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell 2014; 25: 794-808.
37.
Ostendorf BN, Flenner E, Flȍrcken A, et al. Phenotypic characterization of aberrant stem and progenitor cell populations in myelodysplastic syndromes. PLoS ONE 2018; 13: 1-12.
38.
Wang WXX, Du W, Liu W, et al. Detection of molecular targets on the surface of CD34+CD38- bone marrow cells in myelodysplastic syndromes. Cytometry Part A 2010; 77A: 840-848.
39.
Mora-Jensen H, Jendholm J, Rapin N, et al. Cellular origin of prognostic chromosomal aberrations in AML patients. Leukemia 2015; 29: 1785-1789. .
40.
Bill M, Kooten Niekerk PB, Woll PS, et al. Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology. J Cell Mol Med 2018; 22: 2311-2318.
41.
Morsink LM, Walter RB, Ossenkoppelea GJ Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. Blood Rev 2019; 34: 26-33.
42.
Morsink LM, Walter RB Novel monoclonal antibody-based therapies for acute myeloid leukemia. Best Pract Res Clin Haematol 2019; 32: 116-126.
43.
Ma H, Padmanabhan IS, Parmar S, et al. Targeting CLL-1 for acute myeloid leukemia therapy. J Hematol Oncol 2019; 12: 41.
44.
Kenderian SS, Ruella M, Shestova O, et al. Leukemia stem cells are characterized by CLEC12A expression and chemotherapy refractoriness that can be overcome by targeting with chimeric antigen receptor T cells. Blood 2016; 128: 766.
45.
Businesswire.com. iCell gene therapeutics presents first-in-human Data of CLL1-CD33 compound CAR T in refractory acute myeloid leukemia. iCell Gene Therapeutics, LLC. Available from: https://www.businesswire.com/n....
46.
Khan N, Freeman SD, Virgo P, et al. An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38low blasts. Br J Haematol 2015; 170: 80-84.
47.
Wiersma VR, de Bruyn M, Shi C, et al. C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity. MAbs 2015; 7: 321-30.
48.
Bill M, Aggerholm A, Kjeldsen E, et al. Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy. Brit JHaematol 2019; 184: 769-781.
49.
Schuurhuis GJ, Meel MH, Wouters F, et al. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells. PLoS One 2013; 8: 11.
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
